Market Overview

Teva Analyst Says Shares Are Pricing In Too Much Risk

Share:
Teva Analyst Says Shares Are Pricing In Too Much Risk

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), which is beset by fundamental and legal woes, is entering a recovery phase, according to UBS Securities.

The Teva Analyst

Analyst Kevin Caliendo upgraded Teva from Neutral to Buy and lowered the price target from $14 to $12. 

The Teva Thesis

Teva shares have underperformed the broader market, which is overly discounting earnings, business disruption and credit risks, Caliendo said in a Monday upgrade note. (See his track record here.)

The analyst said he sees minimal near-term credit risk for Teva, even in the most stressed environment. The company closed refinancing for near-term expiries in the fourth quarter of 2019 at investment-grade terms, he said. 

While noting that the company has access to over $3 billion in liquidity if needed, Caliendo said he believes its free cash flow will cover outstanding balances.

"Also, our research suggests TEVA's supply chain exposure is manageable, with the biggest risk being if production of key pharmaceutical ingredients in China is halted for closer to ~1+ years vs the ~2 months experienced," the analyst said.

UBS checks suggest production is back online in China and is ramping back toward normal utilization already, he said. 

Taking a conservative stance, UBS lowered its peak estimate for migraine drug Ajovy by about 35%, citing disruption in marketing. The firm also sees risk to the current strong growth in the movement disorder drug Austedo.

UBS made a few estimate changes that left near-term EBITDA unchanged but lowered outyear estimates due to potentially longer growth path for new launches.

"We believe the market is currently pricing in significantly more risk than our estimates would suggest, creating a 3-1 risk-reward skew in the stock here," Caliendo said. 

TEVA Price Action

Teva shares were trading 7.56% higher at $9.04 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations

Co-Diagnostics COVID-19 Test Gets FDA Emergency Use Authorization

Public domain photo via Wikimedia

Latest Ratings for TEVA

DateFirmActionFromTo
Jun 2020SunTrust Robinson HumphreyUpgradesHoldBuy
May 2020UBSMaintainsBuy
May 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Kevin Caliendo UBS SecuritiesAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
WORKPiper SandlerMaintains40.0
TDOCPiper SandlerMaintains220.0
SPWHPiper SandlerMaintains15.0
NTBPiper SandlerMaintains30.0
MDBPiper SandlerMaintains226.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com